BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
Monday, BioNTech SE (NASDAQ:BNTX) reported deeper losses in the second quarter of 2024, with an EPS loss of $(3.62) or (3.36) euros, missing the consensus of (1.89) euros and higher than (79) cents in the second quarter of 2023.
BioNTech SE(NASDAQ:BNTX)于2024年第二季度报告了更深的亏损，每股收益为$(3.62)或(3.36)欧元，低于共识的(1.89)欧元，高于2023年第二季度的(79)美分。
The company reported a net loss of 807.8 million euros compared to 190.4 million euros a year ago.
该公司报告的净亏损为8,078万欧元，相比去年的1,904万欧元有所增加。
The COVID-19 vaccine maker reported sales of 128.7 million euros ($138.56 million), down from 167.7 million euros a year ago and missing the consensus of 157 million euros, reflecting a continued shift in demand from a pandemic to a seasonal endemic COVID-19 vaccine market.
这个生物-疫苗制造商的销售额为1,287万欧元($138.56万美元)，低于去年的16,770万欧元，未达到共识的15,700万欧元，反映出从流行病到季节性免疫COVID-19疫苗市场需求的持续转移。
Also Read: Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?
另请阅读：为什么辉瑞合作伙伴BioNTech股票周一交易走低？
"The year to date has been marked by significant data updates across our oncology portfolio. These readouts reinforce the potential of our platform technologies, including our individualized and off-the-shelf mRNA vaccine platforms, iNeST and FixVac. We have also advanced our strategy by initiating clinical trials evaluating novel combinations of synergistic drug candidates," said Ugur Sahin, CEO and Co-Founder of BioNTech.
“年初至今，我们的肿瘤学组合领域的重要数据不断更新。这些数据验证了我们平台技术的潜力，包括个性化和即用型mRNA疫苗平台，iNeSt和FixVac。我们还通过启动临床试验，评估了协同药物候选人的新型组合，推进了我们的策略。”BioNTech的首席执行官兼联合创始人Ugur Sahin表示。
"In addition, we have started commercializing variant-adapted COVID-19 vaccines for the upcoming season while accelerating our clinical development efforts to realize the full potential of our technologies," Sahin added.
“此外，我们已经开始销售针对即将到来的季节性变异COVID-19疫苗，同时加速我们的临床开发工作，实现我们技术的全部潜力。”Sahin补充道。
R&D expenses increased from 373.4 million euros to 584.6 million euros, mainly influenced by progressing clinical studies for the company's late-stage oncology pipeline candidates.
研发费用从3,734万欧元增加到5,846万欧元，主要是由于推进公司晚期肿瘤学候选线的临床研究所致。
On Monday, Genmab A/S (NASDAQ:GMAB) announced that it will assume sole responsibility for developing and potentially commercializing acasunlimab as BioNTech has opted not to participate in the further development of the acasunlimab program.
周一，Genmab A / S（纳斯达克：GMAB）宣布，由于BioNTech选择不参与acasunlimab计划的进一步发展，因此将独自负责开发和潜在的商业化acasunlimab。
The program will be subject to payment of certain milestones and a tiered single-digit royalty on net sales by Genmab to BioNTech.
该计划将取决于Genmab向BioNTech支付一定的里程碑以及按净销售额支付的分层单位在BioNTech的单个Comirnaty-COVID-19疫苗合作项目中。
Genmab plans to initiate the Phase 3 study in the second half of this year.
Genmab计划在今年下半年启动第3阶段研究。
BioNTech informed the company that it made the decision relating to its portfolio strategy.
BioNTech表示，它是基于组合策略作出决定的。
Guidance: BioNTech said it is still targeting 2024 revenues of 2.5 billion euros to 3.1 billion euros.
指导意见：BioNTech表示，仍然目标2024年收入为25亿欧元至31亿欧元。
Partner Pfizer Inc. (NYSE:PFE) raised its 2024 guidance to $8.5 billion from $8 billion but reaffirmed that $5 billion would come from BioNTech's partnered Comirnaty-COVID-19 vaccine.
合作伙伴辉瑞公司（NYSE: PFE）将其2024年业绩预期从80亿美元上调至85亿美元，但重申其中500亿美元将来自BioNTech合作的Comirnaty-COVID-19疫苗。
Moderna Inc (NASDAQ:MRNA) lowered its 2024 sales guidance on Thursday due to weaker demand for its COVID-19 vaccines.
由于COVID-19疫苗的需求疲软，Moderna Inc（纳斯达克：MRNA）在周四下调了2024年的销售预期。
Price Action: BNTX stock is down 4.08% at $78.66 during the premarket session at last check Monday.
最近一次核查显示，BNTX股票在周一盘前交易中下跌4.08%，至每股78.66美元。
- London High Court Ruling Fuels Pfizer And Moderna Legal Dispute Over COVID-19 Vaccine Patents.
- 伦敦高等法院的裁决加剧了辉瑞和Moderna公司之间的针对COVID-19疫苗专利的法律纠纷。
Photo via Wikimedia Commons
照片通过Wikimedia Commons